menu
    • menu
    [{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Divestment","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnaptysBio \/ DRI Healthcare Trust","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Tesaro","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AnaptysBio \/ Tesaro","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ Tesaro"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"BTLA","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"BTLA","graph1":"Immunology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"BTLA","graph1":"Immunology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Etokimab","moa":"IL-33 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ANB032","moa":"BTLA","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"ANB032","moa":"BTLA","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ TD Cowen"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ANB032","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Imsidolimab","moa":"IL-36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AnaptysBio \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Vanda Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by AnaptysBio

    Menu

    AnaptysBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rosnilimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anaptys’ Rosnilimab Shows Positive RA Phase 2b Results, Highest CDAI LDA

                            Details : ANB030 (rosnilimab) is a subcutaneous PD-1 agonist antibody, which is being evaluated for the treatment of rheumatoid arthritis.

                            Product Name : ANB030

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 12, 2025

                            Lead Product(s) : Rosnilimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rosnilimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anaptys to Reveal Rosnilimab Phase 2b RA Trial Data on Feb 12, 2025

                            Details : ANB030 (rosnilimab) is a subcutaneous PD-1 agonist antibody, which is being evaluated for the treatment of rheumatoid arthritis.

                            Product Name : ANB030

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 11, 2025

                            Lead Product(s) : Rosnilimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imsidolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Vanda Pharmaceuticals

                            Deal Size : $45.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vanda, Anaptys Sign Global License for IL-36R Antagonist Imsidolimab

                            Details : Under the licensing agreement, Vanda will hold the exclusive rights for the development & commercialization of ANB019 (imsidolimab). It is being evaluated for treating Generalized Pustular Psoriasis.

                            Product Name : ANB019

                            Product Type : Antibody

                            Upfront Cash : $10.0 million

                            February 03, 2025

                            Lead Product(s) : Imsidolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Vanda Pharmaceuticals

                            Deal Size : $45.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANB032

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anaptys Announces Phase 2b Trial of ANB032 Did Not Meet Endpoints in Atopic Dermatitis

                            Details : ANB032 is a BTLA agonist antibody candidate, which is being evaluated for the treatment of patients with atopic dermatitis eczema.

                            Product Name : ANB032

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 11, 2024

                            Lead Product(s) : ANB032

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dostarlimab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Sagard Healthcare Partners

                            Deal Size : $50.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Anaptys to Receive $50 Million from Amended Agreement with Sagard for Jemperli Royalties

                            Details : Jemperli (dostarlimab) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.

                            Product Name : Jemperli

                            Product Type : Antibody

                            Upfront Cash : $50.0 million

                            September 05, 2024

                            Lead Product(s) : Dostarlimab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Sagard Healthcare Partners

                            Deal Size : $50.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imsidolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anaptys Reports Positive Results from GEMINI-2 Phase 3 Trial of Imsidolimab in Psoriasis

                            Details : ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.

                            Product Name : ANB019

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 05, 2024

                            Lead Product(s) : Imsidolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANB032

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : TD Cowen

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

                            Details : The net proceeds will be used to fund the clinical development of the company's lead product ANB032 BTLA agonist antibody, which is being evaluated for the treatment of Atopic Dermatitis Eczema.

                            Product Name : ANB032

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            August 14, 2024

                            Lead Product(s) : ANB032

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : TD Cowen

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imsidolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pust...

                            Details : ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.

                            Product Name : ANB019

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 10, 2023

                            Lead Product(s) : Imsidolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dostarlimab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in ...

                            Details : JEMPERLI (dostarlimab-gxly) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.

                            Product Name : Jemperli

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 31, 2023

                            Lead Product(s) : Dostarlimab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rosnilimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

                            Details : ANB030 (Rosnilimab), its investigational wholly owned PD-1 agonist, demonstrates best-in-class activity in vitro with superior inhibition of T cell proliferation, reduction in inflammatory cytokine secretion (Th1, Th2, Th17) and depletion of PD-1+ T cell...

                            Product Name : ANB030

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 01, 2023

                            Lead Product(s) : Rosnilimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth